Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Feb 25, 2026 06:01AM
Sensei Biotherapeutics (SNSE) Halted, News Pending Feb 18, 2026 07:57AM
Sensei Biotherapeutics (SNSE) Misses Q3 EPS by 362c Nov 14, 2025 07:59AM
Sensei Biotherapeutics (SNSE) Misses Q3 EPS by 362c Nov 14, 2025 07:59AM
H.C. Wainwright Downgrades Sensei Biotherapeutics (SNSE) to Neutral Oct 30, 2025 10:58AM


Oct 30, 2025 09:00AM Sensei Biotherapeutics discontinues drug development, explores sale
Oct 30, 2025 08:55AM Sensei Biotherapeutics (SNSE) Halted, News Pending
Oct 17, 2025 08:02AM Sensei Biotherapeutics reports clinical trial results for cancer drug
Oct 16, 2025 02:16PM Sensei Biotherapeutics (SNSE) halted on volatility
Aug 5, 2025 09:42AM Sensei Biotherapeutics (SNSE) PT Raised to $30 at H.C. Wainwright
Jun 13, 2025 07:30AM Sensei Biotherapeutics (SNSE) Announces 1:20 Reverse Share Split
Jun 2, 2025 06:39AM H.C. Wainwright Assumes Sensei Biotherapeutics (SNSE) at Buy
May 6, 2025 04:34PM Sensei Biotherapeutics, Inc. (SNSE) Misses Q1 EPS by 4c
Mar 28, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Sensei Biotherapeutics (SNSE)
Mar 27, 2025 04:05PM Sensei Biotherapeutics (SNSE) Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
Nov 14, 2024 07:35AM Sensei Biotherapeutics, Inc. (SNSE) Tops Q3 EPS by 2c
Aug 6, 2024 08:58AM Sensei Biotherapeutics, Inc. (SNSE) Tops Q2 EPS by 1c